Tirzepatide

weight loss

Tirzepatide (GLP-1/GIP Dual Agonist)

Mechanism of Action

A dual GLP-1 and GIP receptor agonist combining appetite suppression with enhanced metabolic effects. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management).

Common Doses

2.5mg

1x weeklysubcutaneous

5mg

1x weeklysubcutaneous

Common Protocols

Dose Escalation16-28 weeks

Start 2.5mg/week, increase by 2.5mg every 4 weeks

Safety Notes

FDA-approved. Similar GI side effects to semaglutide. May offer greater weight loss in head-to-head trials.

Legal Status

United States

FDA Approved

Australia

TGA Approved

United Kingdom

MHRA Approved

Ready to track this peptide?

Start Experiment

This information is for educational purposes only. N1X does not recommend, endorse, or facilitate access to any substance. Always consult a qualified healthcare provider before starting any protocol.